Announcements Trials
Browse Landscape

Phase

Phase NA 1Phase 3 1Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Anus Neoplasms 1Anal Canal Carcinoma 1

Interventions

pembrolizumab 222Carboplatin 216Cisplatin 204Paclitaxel 181Gemcitabine 148Docetaxel 125Capecitabine 114Dexamethasone 102Cyclophosphamide 102Pemetrexed 101Specimen Handling 99Magnetic Resonance Spectroscopy 97Oxaliplatin 95Radiotherapy 94Doxorubicin 90Fluorouracil 87Bevacizumab 82Nivolumab 73Leucovorin 72Rituximab 70durvalumab 66Vincristine 66Lenalidomide 64Etoposide 61atezolizumab 59Radiation 59Irinotecan 59130-nm albumin-bound paclitaxel 56Prednisone 55Letrozole 52

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 3 × Proctoscopy × 1 year × Clear all
NCT03233711 2026-05-13

Nivolumab After Combined Modality Therapy in Treating Patients With High Risk Stage II-IIIB Anal Cancer

National Cancer Institute (NCI)

Phase 3 Active not recruiting
344 enrolled
Gastrointestinal

Anal Canal Carcinoma, Anus Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡